[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 175
1. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Gläsker S, Sohn TS, Zeng W, Ikejiri B, Proescholdt MA, Mayer C, Weil RJ, Oldfield EH, Zhuang Z: Comparative proteomic profiles of meningioma subtypes. Cancer Res; 2006 Oct 15;66(20):10199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics.
  • Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors.
  • Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone.
  • Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas.
  • The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningioma / classification

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047085.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


2. Wiemels J, Wrensch M, Claus EB: Epidemiology and etiology of meningioma. J Neurooncol; 2010 Sep;99(3):307-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most meningiomas are encapsulated and benign tumors with limited numbers of genetic aberrations, their intracranial location often leads to serious and potentially lethal consequences.
  • They are the most frequently diagnosed primary brain tumor accounting for 33.8% of all primary brain and central nervous system tumors reported in the United States between 2002 and 2006.
  • Because women are twice as likely as men to develop meningiomas and these tumors harbor hormone receptors, an etiologic role for hormones (both endogenous and exogenous) has been hypothesized.
  • Growing emphasis on brain tumor research coupled with the advent of new genetic and molecular epidemiologic tools in genetic and molecular epidemiology promise hope for advancing knowledge about the causes of intra-cranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Brain Pathol. 2010 Jul;20(4):751-62 [20015288.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):203-7 [11158188.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):252-9 [11979441.001]
  • [Cites] Neurology. 2002 Jun 25;58(12):1849-52 [12084890.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1555-63 [12381708.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):260-3 [12800203.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):848-53 [14609164.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1026-34 [14983499.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1208-12 [15022288.001]
  • [Cites] Neurosurgery. 1979 Mar;4(3):203-6 [460549.001]
  • [Cites] J Natl Cancer Inst. 1980 Jul;65(1):67-73 [6930521.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Neuroepidemiology. 1990;9(2):106-11 [2333123.001]
  • [Cites] Cancer. 1992 May 15;69(10):2541-7 [1568177.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):456-62 [8433149.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):91-5 [1306734.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:50-3 [8738495.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):389-93 [9247278.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):109-16 [9486470.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):969-76 [15824172.001]
  • [Cites] Surg Neurol. 2005 Jun;63(6):550-3; discussion 553 [15936382.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1784-90 [16030117.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1152-7 [16570277.001]
  • [Cites] BMC Cancer. 2006;6:152 [16759391.001]
  • [Cites] Am J Epidemiol. 2006 Oct 1;164(7):629-36 [16835295.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):1-7 [16703453.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] BMC Genomics. 2007;8:16 [17222329.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] J Neurooncol. 2007 May;82(3):229-37 [17151932.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):471-6 [17580362.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61 [17684142.001]
  • [Cites] Am J Epidemiol. 2007 Oct 15;166(8):941-50 [17646205.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50 [17925535.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1821-8 [17978290.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):270-6 [18270339.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):185-90 [18560401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2663-70 [18843008.001]
  • [Cites] Ann Epidemiol. 2009 Mar;19(3):161-71 [19216998.001]
  • [Cites] Acta Neurochir (Wien). 2009 Mar;151(3):239-44; discussion 244 [19238320.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):481-8 [19356978.001]
  • [Cites] Eur J Epidemiol. 2009;24(8):433-40 [19484497.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):414-22 [19001526.001]
  • [Cites] Childs Nerv Syst. 2009 Nov;25(11):1411-7 [19636568.001]
  • [Cites] J Neurosurg. 2010 May;112(5):920-4 [19731987.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1356-61 [20406964.001]
  • [Cites] Int J Epidemiol. 2010 Jun;39(3):675-94 [20483835.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3001-7 [11122586.001]
  • (PMID = 20821343.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109468; United States / NCI NIH HHS / CA / R01 CA109745-05; United States / NCI NIH HHS / CA / R01 CA109745-04; United States / NCI NIH HHS / CA / CA109745; United States / NCI NIH HHS / CA / CA52689; United States / NCI NIH HHS / CA / R01 CA109468; United States / NCI NIH HHS / CA / R01 CA109745-03; United States / NCI NIH HHS / CA / CA109461; United States / NCI NIH HHS / CA / R01 CA151933; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA108473; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / R01 CA109461; United States / NCI NIH HHS / CA / R01 CA109745-02; United States / NCI NIH HHS / CA / R01 CA109475; United States / NCI NIH HHS / CA / R01 CA109745; United States / NCI NIH HHS / CA / CA109475; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2945461
  •  go-up   go-down


3. Fukuoka S: [Stereotactic irradiation (Gamma knife) for benign brain tumors]. Nihon Rinsho; 2005 Sep;63 Suppl 9:412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic irradiation (Gamma knife) for benign brain tumors].
  • [MeSH-major] Cochlear Nerve. Cranial Nerve Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201556.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


Advertisement
4. Sturges BK, Dickinson PJ, Bollen AW, Koblik PD, Kass PH, Kortz GD, Vernau KM, Knipe MF, Lecouteur RA, Higgins RJ: Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med; 2008 May-Jun;22(3):586-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial meningiomas are the most common primary brain tumors in dogs.
  • Classification of meningiomas by tumor grade and subtype has not been reported, and the value of magnetic resonance imaging (MRI) characteristics for predicting tumor subtype and grade has not been investigated.
  • HYPOTHESIS: Canine intracranial meningiomas are a heterogenous group of tumors with differing histological subtypes and grades.
  • ANIMALS: One hundred and twelve dogs with a histological diagnosis of intracranial meningioma.
  • The incidence of specific tumor grades was 56% benign (Grade I), 43% atypical (Grade II), and 1% malignant (Grade III).
  • No statistically significant (P < .05) associations were found among tumor subtype or grade and any of the MRI features studied.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Meningiomas in dogs differ from their counterparts in humans mainly in their higher incidence of atypical (Grade II) tumors observed.
  • MRI characteristics do not allow for prediction of meningioma subtype or grade, emphasizing the necessity of histopathology for antemortem diagnosis.
  • The higher incidence of atypical tumors in dogs may contribute to the poorer therapeutic response in dogs with meningiomas as compared with the response in humans with meningiomas.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466258.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol; 2010 Dec;12(12):1278-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal.
  • Understanding the potential behavior of these tumors in individual patients is critical for rational therapeutic decision-making.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 6 / genetics. Histones / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):708-15 [12861068.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14 [14506147.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):939-43 [15375526.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1199-212 [16377562.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9113-26 [18258596.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] Mol Cancer. 2008;7:93 [19099607.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Biofactors. 2009 Mar-Apr;35(2):200-8 [19449449.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1395-407 [19885562.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2584-93 [19847810.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • (PMID = 20685720.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones
  • [Other-IDs] NLM/ PMC3018937
  •  go-up   go-down


6. Liu AL, Wang C, Sun S, Wang M, Liu P: Gamma knife radiosurgery for tumors involving the cavernous sinus. Stereotact Funct Neurosurg; 2005;83(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for tumors involving the cavernous sinus.
  • OBJECTIVE: To study the features of diagnosis and radiosurgery of tumors involving the cavernous sinus.
  • Our experience of treating cavernous sinus tumors by GK was analyzed retrospectively.
  • RESULTS: A Hundred and forty-four (82.3%) patients were followed from 1 to 84 months (median 32.5 months); total tumor control rate was 94%.
  • Surgery was performed after radiosurgery in 3 patients because of tumor enlargement.
  • Metastatic tumor in the cavernous sinus was highly sensitive to irradiation.
  • CONCLUSION: With high tumor control rate and few complications, GK surgery could become a main option for small benign or residual tumors involving the cavernous sinus.
  • It is also very useful as part of comprehensive therapy for metastatic tumors in the cavernous sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma / surgery. Radiosurgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adolescent. Adult. Aged. Child. Chordoma / pathology. Chordoma / surgery. Female. Follow-Up Studies. Hemangioma, Cavernous / pathology. Hemangioma, Cavernous / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860936.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Wang Y, Kang L, Xiao L: Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute. Jpn J Ophthalmol; 2009 Nov;53(6):629-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute.
  • RESULTS: The number and percentage of lesions in each general category were leukemia lesions in eight patients (19.5%), metastatic tumors in seven (17%), optic nerve and meningeal tumors in six (14.6%), secondary tumors in six (14.6%), peripheral nerve lesions in four (9.8%), inflammatory lesions in four (9.8%), and vasculogenic, histiocytic, and miscellaneous lesions, each in two patients (4.9%).
  • Of all cases, 51.2% were benign and 48.8% were malignant.
  • Of the 15 patients with either metastatic tumors or blood disorders, two (13.3%) had a history of primary neoplasm at presentation.
  • Through the combination of history, bilateral ocular manifestations, radiologic findings, and systemic examinations, the correct diagnosis can be made, which is valuable for early identification of both metastasis and blood disorders.
  • [MeSH-major] Orbital Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2002 Apr;109(4):753-6 [11927435.001]
  • [Cites] Surv Ophthalmol. 2004 May-Jun;49(3):281-99 [15110666.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):723-6 [6022244.001]
  • [Cites] Arch Ophthalmol. 2005 Oct;123(10 ):1443-5 [16219741.001]
  • [Cites] Arch Ophthalmol. 1971 Jun;85(6):673-5 [5562786.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Dec;10(4):283-6 [7865452.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17 (5):346-54 [11642491.001]
  • [Cites] Acta Chir Plast. 2003;45(2):49-51 [12921259.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9 [11733333.001]
  • [Cites] Ophthalmology. 1990 Nov;97(11):1519-31 [2255524.001]
  • [Cites] Arch Ophthalmol. 1990 Jan;108(1):80-3 [2105089.001]
  • [Cites] Br J Ophthalmol. 1992 Dec;76(12):755-7 [1486082.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Surv Ophthalmol. 1992 Nov-Dec;37(3):167-83 [1475751.001]
  • [Cites] Ophthalmology. 2003 Oct;110(10):2019-30 [14522782.001]
  • [Cites] Eye (Lond). 2008 Jul;22(7):980-1 [18049485.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):537-41 [11874758.001]
  • [Cites] Am J Ophthalmol. 1990 Aug 15;110(2):153-9 [2198811.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2007 Mar-Apr;23(2):87-93 [17413619.001]
  • [Cites] Ophthalmology. 1997 Apr;104(4):683-94 [9111264.001]
  • [Cites] Arch Ophthalmol. 1984 Nov;102(11):1606-11 [6497741.001]
  • (PMID = 20020243.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Beseoglu K, Knobbe CB, Reifenberger G, Steiger HJ, Stummer W: Supratentorial meningeal melanocytoma mimicking a convexity meningioma. Acta Neurochir (Wien); 2006 Apr;148(4):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial meningeal melanocytoma mimicking a convexity meningioma.
  • OBJECTIVE AND IMPORTANCE: Meningeal melanocytomas are rare benign neuro-ectodermal tumors arising from melanocytic cells in the leptomeninges.
  • Thus, most reported cases of meningeal melanocytomas are located in the posterior fossa and the spinal cord, respectively.
  • CLINICAL PRESENTATION: We report on the rare case of a 55-year-old male patient with a large supratentorial meningeal melanocytoma mimicking a convexity meningioma and a smaller, similarly dura based lesion in the posterior fossa.
  • INTERVENTION: Tumor control to date was achieved by surgery of the large lesion and radiosurgery of the small lesion.
  • CONCLUSION: Complete tumor resection may be advantageous and second or recurrent lesions may be managed by repeat surgery or stereotactic radiosurgery.
  • [MeSH-major] Melanocytes / pathology. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Neoplasms, Multiple Primary / pathology. Nevus / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors / prevention & control. Humans. Magnetic Resonance Imaging. Male. Meninges / pathology. Middle Aged. Neurosurgical Procedures. Parietal Lobe / pathology. Parietal Lobe / surgery. Radiosurgery. Rare Diseases. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391879.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


9. Schaller B: Spinal meningioma: relationship between histological subtypes and surgical outcome? J Neurooncol; 2005 Nov;75(2):157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraspinal meningiomas are slow growing benign tumors that produce indolent neurological deficits, which are often reversible following operation.
  • Mean age of the 30 women (91%) and the 3 men (9%) was 63+/-20 years (range 22-88).
  • Tumor position was laterally in 19 (58%), posteriorly in 8 (24%) and anteriorly in 6 (18%) patients.
  • Following tumor resection, neurological deficits resolved in 26 of 33 patients (79%) and worsened in 7 of 33 patients (21%) all of the latter had meningiomas of the psammomatous type.
  • Posterior or lateral tumor position in the spinal canal, location below C4, age less than 60 years, and duration of preoperative symptoms seem to be correlated with a good outcome.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / pathology. Meningioma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Angiography. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Myelography. Neoplasm Recurrence, Local. Neurologic Examination. Prognosis. Regression Analysis. Retrospective Studies. Sex Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Tumor Burden. X-Rays

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurosurg. 1982 Dec;57(6):804-12 [7143063.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):253-6 [3003263.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):353-60 [422988.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Acta Neurol Scand. 1988 Jan;77(1):27-30 [3354308.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):465-71 [10392201.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):629-31 [2234369.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Feb;112(2):228-34 [7838543.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):646-8 [2926506.001]
  • [Cites] Ann Surg. 1940 Apr;111(4):513-30 [17857556.001]
  • [Cites] J Neurosurg. 1987 May;66(5):695-700 [3572496.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):153-60 [2671779.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • (PMID = 16132511.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Lee JH, Sade B, Choi E, Golubic M, Prayson R: Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg; 2006 Jul;105(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors analyzed the relationship between the tumors' histological subtypes and sites of origin in the 731 patients from this group who harbored tumors that were determined to be benign histologically (World Health Organization Grade I).
  • Meningothelial meningiomas (MMs) accounted for 63.5% (464/731) of the Grade I tumors.
  • Analysis of the increasingly available data on genetic and topographic characteristics of MMs suggests that they may represent a unique entity, contrary to the prevailing belief that all benign meningiomas are identical tumors.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Base Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Humans. Meninges / embryology. Retrospective Studies

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871881.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


13. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • Although their behavior is usually benign, they tend to recur even after total removal, and their recurrence is dependent on different aspects.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Complete removal of the tumor was possible in 86.7% in both studies.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiosurgery. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Saraceni C, Harrop JS: Spinal meningioma: chronicles of contemporary neurosurgical diagnosis and management. Clin Neurol Neurosurg; 2009 Apr;111(3):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma: chronicles of contemporary neurosurgical diagnosis and management.
  • Notwithstanding their overwhelmingly benign propensity, the occurrence of extramedullary meningioma may nonetheless cause significant morbidity and possible mortality.
  • The rapidity of diagnosis and the first neurosurgical encounter are cornerstones in patient longevity and neurological preservation.
  • However, surgical candidacy may be limited, particularly in those patients with significant preexisting medical comorbidities, aggressive or recurring tumors, or multiple lesions.
  • A review on neurosurgical diagnosis and treatment modalities in the management of spinal meningioma is therefore pertinent.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / surgery. Microsurgery / methods. Radiosurgery / methods


15. Woo KS, Sung KS, Kim KU, Shaffer LG, Han JY: Characterization of complex chromosome aberrations in a recurrent meningioma combining standard cytogenetic and array comparative genomic hybridization techniques. Cancer Genet Cytogenet; 2008 Jan 1;180(1):56-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas were among the first solid tumors recognized as having cytogenetic alterations.
  • The vast majority of meningiomas are histologically benign, but the prognosis is determined by risk of recurrence after surgical treatment.
  • Despite important advances in the identification of prognostic factors in the past decade, the exact nature of tumor recurrence remains largely unknown.
  • Cytogenetic analysis at diagnosis revealed the following complex numerical and structural aberrations: 42,XY,der(1)t(1;?
  • )(p12;? ),-6,der(12;15)(q10;q10),-18, -22.
  • The presence of a complex cytogenetic profile and progression-associated chromosomal abnormalities in a benign meningioma suggests the existence of underlying molecular events.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Meningeal Neoplasms / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068535.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas represent the second most common central nervous system neoplasms in adults and account for 26% of all primary brain tumors.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • In the univariate analysis, Ki-67 labeling index and postoperative Karnofsky performance status were identified as significant prognostic factors of tumor recurrence and overall survival.
  • The multivariate analysis demonstrated that Ki-67 labeling index is the only independent predictor of both tumor recurrence and overall survival.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


17. Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS; 2009 Sep;117(9):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma is a common neoplasm that constitutes almost 30% of all primary central nervous system tumors and is associated with inconsistent clinical outcomes.
  • The extracellular matrix proteins play a crucial role in meningioma cell biology and are important in tumor cell invasion and in progression to malignancy.
  • The aim of this study was to evaluate the expression of SPARC with proliferation index, p53 reactivity in WHO grade 1 (benign), grade 2 (atypical) and grade 3 (anaplastic) meningiomas and correlate with clinical features of the patients, including location of the tumor, recurrence of the tumor and survival of patients.
  • We studied 111 meningiomas, 69 being benign, 34 being atypical and eight being anaplastic meningiomas of various histological types.
  • Immunohistochemical scores of SPARC were determined as the sum of frequency (0-3) and intensity (0-3) of immunolabeling of the tumor cells.
  • A high immunohistochemical score (4-6) for SPARC was more frequent in atypical and in anaplastic meningiomas than in benign meningiomas (p < 0.01).
  • MIB-1 proliferation index showed significant association between tumor grades in meningiomas (p < 0.01).
  • At the end of a follow-up period of 47.53 +/- 25.04 months, 30 tumors recurred.
  • A high SPARC expression was significantly associated with tumor recurrence (p = 0.02).
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Osteonectin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Recurrence. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703125.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Osteonectin; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


18. Tabernero MD, Espinosa AB, Maíllo A, Sayagués JM, Alguero Mdel C, Lumbreras E, Díaz P, Gonçalves JM, Onzain I, Merino M, Morales F, Orfao A: Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features. Am J Clin Pathol; 2005 May;123(5):744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases with gain or monosomy corresponded more frequently to histologically malignant tumors (P = .009).
  • The 2 patients with loss limited to 14q31-q32 had histologically benign tumors and no relapse after more than 5 years' follow-up.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 14. In Situ Hybridization, Fluorescence / methods. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Interphase. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981814.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • There was no relationship between the location of the tumor and the histopathological features.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


20. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Asanuma K, Kasai Y, Takegami K, Ito H, Yoshikawa T, Uchida A: Spinal neurocutaneous melanosis without cutaneous nevi. Spine (Phila Pa 1976); 2008 Oct 1;33(21):E798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To show a case and review the epidemiology, diagnosis and treatment of neurocutaneous melanosis without cutaneous nevi.
  • SUMMARY OF BACKGROUND DATA: Neurocutaneous melanosis is a rare congenital syndrome consisting of benign or malignant melanocytic tumors of the central nervous system and cutaneous nevi.
  • In general, patients are treated with palliative therapy, such as shunt placement to reduce intracranial pressure or tumor resection to reduce compression of the brain or spine.
  • Magnetic resonance imaging (MRI) of the spine revealed intradural tumor at the T5 level.
  • Computed tomography myelography showed intradural extramedullary tumor.
  • After the pigmented dura was opened, a pigmented tumor was resected.
  • RESULTS: Histologically, the pigmented tumor represented low grade.
  • The pigmented dura and bone comprised melanin-bearing cells without tumor cells.
  • Meningeal melanocytoma with leptomeningeal melanosis in the absence of cutaneous nevi was diagnosed.
  • CONCLUSION: This patient displayed spinal meningeal melanocytoma and leptomeningeal melanosis without cutaneous nevi.
  • The diagnosis in this case was speculated to represent a forme fruste of neurocutaneous melanosis.
  • [MeSH-major] Melanosis / radiography. Meningeal Neoplasms / radiography. Neurocutaneous Syndromes / radiography
  • [MeSH-minor] Adult. Humans. Male. Nevus, Intradermal / radiography. Nevus, Intradermal / surgery. Skin Neoplasms / radiography. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Neurocutaneous melanosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827686.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • These tumors constitute a difficult clinical problem to handle.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Saceda-Gutiérrez JM, Isla-Guerrero AJ, Pérez-López C, Ortega-Martínez R, Gómez de la Riva A, Gandia-González ML, Gutiérrez-Molina M, Rey-Herranz JA: [Solitary fibrous tumors of the meninges: report of three cases and literature review]. Neurocirugia (Astur); 2007 Dec;18(6):496-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumors of the meninges: report of three cases and literature review].
  • [Transliterated title] Tumor fibroso solitario meníngeo: descripción de tres casos y revisión de la literatura.
  • We report 3 patients with fibrous solitary tumor of meningeal location where we described the histological study, as well as evolution after the surgical treatment.
  • Checking the literature the tumor is indistinguishable clinical and radiolocally of the typical meningioma, doing necessary the use of inmunohistochemistry to do the differential diagnosis, where positiveness for CD34 and the negativeness for EMA define the fibrous solitary tumor.
  • It is about a benign tumor, where total removing is the principal factor in prognosis, nevertheless there are cases of local recurrences and long-distance metastasis.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Solitary Fibrous Tumors / pathology. Solitary Fibrous Tumors / radiography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094909.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 46
  •  go-up   go-down


24. Norden AD, Drappatz J, Wen PY: Advances in meningioma therapy. Curr Neurol Neurosci Rep; 2009 May;9(3):231-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common primary brain tumors in adults.
  • Most of them are benign (World Health Organization grade I), slow-growing lesions, but some are classified as atypical (WHO grade II) or malignant (WHO grade III).
  • Surgical resection is curative when complete removal of a benign meningioma is possible.
  • Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zentralbl Neurochir. 2005 Feb;66(1):17-23 [15744624.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):161-2 [15762200.001]
  • [Cites] J Biomed Opt. 2005 Nov-Dec;10(6):064026 [16409091.001]
  • [Cites] N Engl J Med. 2007 Dec 6;357(23):2411-2 [18057351.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):251-9 [18365142.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):471-6 [17580362.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5295-303 [16707455.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61 [17684142.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):107-13; discussion 107-13 [15987576.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E9 [17961046.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E11 [17961035.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2007 May;83(1):33-8 [17245625.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1204-12 [18953429.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Nov;187(1):25-7 [18992637.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):87-93 [18617056.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] J Neurol. 2008 Jun;255(6):891-5 [18350353.001]
  • [Cites] Curr Med Chem. 2008;15(8):826-33 [18393851.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17 (10 ):2663-70 [18843008.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Hybridoma. 2001 Apr;20(2):131-6 [11394532.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6 Suppl 3):1115-21; discussion 1121-3 [18695533.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):147-56 [17594108.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):270-6 [18270339.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3 Suppl 1):102-3; discussion 103-4 [18424972.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E5 [17961042.001]
  • [Cites] Cancer Genet Cytogenet. 2008 May;183(1):14-20 [18474292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):61-9; discussion 69-70 [18300892.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E2 [18447741.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):495-503; discussion 503-4 [17881961.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] BMC Cancer. 2006 Jun 07;6:152 [16759391.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] BMC Genomics. 2007 Jan 12;8:16 [17222329.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1473-80 [17557299.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • (PMID = 19348712.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 81
  •  go-up   go-down


25. Sayagués JM, Tabernero MD, Maíllo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A: Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol; 2006 May;65(5):445-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen spinal and 141 intracranial meningioma patients were analyzed at diagnosis.
  • In all tumors, interphase fluorescence in situ hybridization (iFISH) studies were performed for the detection of quantitative abnormalities for 11 different chromosomes.
  • Additionally, microarray analyses were performed on a subgroup of 18 histologically benign meningiomas (7 spinal and 11 intracranial).
  • Upon comparison with intracranial tumors, spinal meningiomas showed a marked predominance of psammomatous and transitional tumors (p = 0.001), together with a higher proportion of cases displaying a single tumor cell clone by iFISH (p = 0.004).
  • In 86% of the spinal versus 56% of the intracranial tumors (p = 0.01), the ancestral tumor cell clone detected showed either absence of any chromosomal abnormality or monosomy 22/22q- alone.
  • Analysis of gene expression profiles showed differential expression between spinal and intracranial meningiomas for a total of 1555 genes, 35 of which allowed a clear distinction between both tumor types.
  • Most of these 35 genes (n = 30) showed significantly higher expression among spinal tumors and corresponded to genes involved in signal transduction pathways, which did not show a significantly different expression according to tumor histopathology.
  • [MeSH-major] Gene Expression / physiology. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772868.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


26. Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H: Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol; 2006 Oct;80(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormonal status was determined in 510 tumor samples.
  • 443 samples were from primary meningiomas and 67 from recurrent tumors.
  • Of the samples, 455 were benign (WHO grade I), 49 atypical (grade II), and 6 malignant (grade III).
  • Of the primary tumor samples, 88% were progesterone receptor positive, 40% were positive for estrogen and 39% for androgen receptors.
  • Estrogen positive tumor samples had significantly higher proliferation index than estrogen negative samples.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Androgen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Clin Neuropharmacol. 1984;7(4):363-7 [6509448.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir (Wien). 1992;115(1-2):20-30 [1595392.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1312-6 [8443810.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):453-60 [7861224.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):92-7 [8587697.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1327-33; discussion 1333-4 [12762878.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1958 May;21(2):89-91 [13539648.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):750-5 [2213165.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):848-53 [14609164.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):456-62 [8433149.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3570-5 [10999746.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1049-55 [8584144.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1152-9 [9361071.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):527-34 [8113866.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 1986 Jul;65(1):99-107 [3712034.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):679-85 [8033047.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):396-406 [2172119.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] J Surg Oncol. 1986 Mar;31(3):182-3 [3724170.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):765-73 [7523635.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1420-7 [9865827.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):743-9 [2213164.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):245-9 [4023903.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:50-3 [8738495.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Endocrinology. 1994 Jul;135(1):107-12 [8013342.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):184-7 [8027799.001]
  • [Cites] Surg Neurol. 1995 Mar;43(3):230-3; discussion 234 [7792684.001]
  • [Cites] J Neurooncol. 1999 Apr;42(2):109-16 [10421067.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • (PMID = 16703453.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


27. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res; 2005 Jun 1;11(11):4074-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Activation of intracellular signaling cascades has been implicated in the growth control of benign meningiomas, but their role for meningioma progression and outcome is unknown.
  • Here we determined the expression and function of proteins involved in mitogen-activated protein kinase (MAPK) and phosphinositol-3 kinase (PI3K)/Akt signaling in benign, atypical, and malignant meningiomas and studied their association with clinicopathologic data including meningioma recurrence.
  • EXPERIMENTAL DESIGN: Expression of various MAPK and PI3K signaling proteins was determined in 70 primary meningiomas and, if present, in recurrent tumors by immunohistochemistry and Western blotting.
  • The expression patterns in primary and recurrent tumors were related to clinical data.
  • RESULTS: Atypical and malignant meningiomas showed higher levels of phospho-Akt compared with benign tumors, and their proliferation could be inhibited by PI3K blocking using wortmannin.
  • In contrast, expression of phospho-Raf and phospho-MAPK was decreased in aggressive meningiomas compared with benign tumors, but MAPK inhibition by PD98059 resulted in tumor cell apoptosis and decreased proliferation.
  • CONCLUSIONS: Both MAPK and PI3K/Akt pathways are activated at different levels in benign and malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Mitogen-Activated Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Aged. Androstadienes / pharmacology. Apoptosis / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Enzyme Activation. Female. Flavonoids / pharmacology. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / analysis. Male. Middle Aged. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phospholipase C gamma. Platelet-Derived Growth Factor / analysis. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-akt. Signal Transduction. Tumor Cells, Cultured. Type C Phospholipases / analysis. raf Kinases / analysis. ras Proteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930342.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Androstadienes; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Platelet-Derived Growth Factor; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.3 / Phospholipase C gamma; EC 3.6.5.2 / ras Proteins; XVA4O219QW / wortmannin
  •  go-up   go-down


28. Ong L, Ferrucci S: Tuberculum sellae meningioma associated with lymphomatoid papulosis. Optometry; 2005 Mar;76(3):165-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a tuberculum sellae meningioma concurrent with lymphomatoid papulosis, a T-cell lymphomatoid skin disorder.
  • CONCLUSION: Meningiomas are generally benign tumors that can cause symptoms if vital structures are compromised.
  • Altered visual function and optic atrophy may be the only presentation of intracranial and orbital tumors.
  • Lymphomatoid papulosis (LyP) is a rare cutaneous disorder involving infiltrating clonal T-cells that has been associated with disseminated lymphomatic skin tumors.
  • [MeSH-major] Lymphomatoid Papulosis / complications. Meningeal Neoplasms / complications. Meningioma / complications. Optic Atrophy / etiology. Sella Turcica / pathology. Vision Disorders / etiology


29. Kawahara I, Nakamoto M, Matsuo Y, Tokunaga YI, Abe K: [A case of rapidly growing dumbbell-shaped convexity meningioma]. No Shinkei Geka; 2009 Jun;37(6):579-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapidly growing meningiomas are unusual because meningiomas are generally benign and slow-growing tumors.
  • The author describes a rare case of a rapidly growing dumbbell-shaped convexity meningioma in an elderly patient.
  • The tumor was removed completely (Simpson grade II), and the pathological diagnosis was atypical meningioma.
  • There was a difference of MIB-1 LI within the tumor, which suggests that the difference of proliferation within the meningioma may have changed it into "dumbbell-shaped".
  • This represents an interesting example of a rapidly growing meningiomas.
  • [MeSH-major] Meningeal Neoplasms / radiography. Meningioma / radiography

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522286.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


30. Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, Lim CC: Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol; 2008 Jun;29(6):1147-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.
  • BACKGROUND AND PURPOSE: Atypical and malignant meningiomas are uncommon tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared with benign tumors.
  • We investigated the utility of diffusion-weighted (DW) MR imaging to differentiate atypical/malignant from benign meningiomas and to detect histologic dedifferentiation to higher tumor grade.
  • MATERIALS AND METHODS: We retrospectively compared conventional and DW MR images (b-value 1000 s/mm(2)) acquired on a 1.5T clinical scanner between 25 atypical/malignant and 23 benign meningiomas.
  • RESULTS: Irregular tumor margins, peritumoral edema, and adjacent bone destruction occurred significantly more often in atypical/malignant than in benign meningiomas.
  • The mean ADC of atypical/malignant meningiomas (0.66 +/- 0.13 x 10(-3) mm(2)/s) was significantly lower compared with benign meningiomas (0.88 +/- 0.08 x 10(-3) mm(2)/s; P < .0001).
  • Mean NADC ratio in the atypical/malignant group (0.91 +/- 0.18) was also significantly lower than the benign group (1.28 +/- 0.11; P < .0001), without overlap between groups.
  • Two patients had isointense benign tumors on initial DW MR imaging, and these became hyperintense with the decrease in ADC and NADC below these thresholds when they progressed to atypical and malignant meningiomas on recurrence.
  • CONCLUSIONS: ADC and NADC ratios in atypical/malignant meningiomas are significantly lower than in benign tumors.
  • Decrease in ADC and NADC on follow-up imaging may suggest dedifferentiation to higher tumor grade.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2009 Feb;30(2):E21 [19193747.001]
  • (PMID = 18356472.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W: Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch; 2006 Nov;449(5):529-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas in general are circumscribed slow-growing tumors.
  • However, despite gross total resection, tumor relapse and patients' outcome are still an issue.
  • (3) subtotal tumor resection;.
  • In particular, biologically aggressive meningiomas of histologically benign or "borderline" phenotype could be therefore identified by ALPL detection followed by 1p in situ hybridization.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1986 Mar;45(2):95-107 [3005518.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):305-13 [3022913.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):252-8 [16040297.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1014-20 [14749765.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Nature. 1967 Oct 7;216(5110):84-5 [6050684.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer Genet Cytogenet. 1982 Jul;6(3):249-74 [6288229.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):170-4 [16033133.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):879-86 [9258258.001]
  • [Cites] Clin Neuropathol. 2006 Mar-Apr;25(2):67-73 [16550739.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Arch Pathol Lab Med. 1999 Sep;123(9):793-800 [10458826.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 17016718.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


32. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


33. Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, Flickinger JC: Stereotactic radiosurgery for convexity meningiomas. J Neurosurg; 2009 Sep;111(3):458-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors were located in frontal (80 patients), parietal (24 patients), temporal (12 patients), and occipital (9 patients) areas.
  • The WHO tumor grades in patients with prior resections were Grade I in 34 patients, Grade II in 15 patients, and Grade III in 6 patients.
  • Seventy patients underwent primary radiosurgery and therefore had no prior histological tumor diagnosis.
  • The mean tumor volume was 7.6 ml.
  • Radiosurgery was performed using the Leksell Gamma Knife with a mean tumor margin dose of 14.2 Gy.
  • After primary radiosurgery, the tumor control rate was 92%.
  • After adjuvant radiosurgery, the control rate was 97% for Grade I tumors.
  • The actuarial tumor control rates at 3 and 5 years for the entire series were 86.1+/-3.8% and 71.6+/-8.6%, respectively.
  • For patients with benign tumors (Grade I) and those without prior surgery, the actuarial tumor control rate was 95.3+/-2.3% and 85.8+/-9.3%, respectively.
  • No patient developed a subsequent radiation-induced tumor.
  • CONCLUSIONS: Stereotactic radiosurgery provides satisfactory control rates either after resection or as an alternate to resection, particularly for histologically benign meningiomas.
  • Its role is most valuable for patients whose tumors affect critical neurological regions and who are poor candidates for resection.
  • Both temporary and permanent morbidity are related to brain location and tumor volume.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Female. Humans. Male. Neurofibromatosis 2 / complications. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199473.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Poliani PL, Sperli D, Valentini S, Armentano A, Bercich L, Bonetti MF, Corriero G, Brisigotti M, Quattrone A, Lanza PL: Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case. Neuropathology; 2009 Oct;29(5):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case.
  • Cerebral and spinal location of glioneuronal tumors have been recently described as a novel type of primary CNS neoplasia.
  • A distinctive rare form of glioneuronal tumors with neuropil-like islands (GTNI) have been reported to occur in the adult cerebrum, whereas spinal GTNI localization is extremely rare.
  • In the present report we describe a case of a 15-month-old child with a spinal GTNI of the cervical region and meningeal dissemination.
  • Histologically the tumor was composed of round, small neurocytic-like cells arranged around eosinophilic neuropil cores and embedded in a diffuse fibrillar glial component forming prominent "rosetted" neuropil islands displaying strong immunoreactivity for neuronal markers.
  • Nevertheless, due to their exceptional rarity, the natural history of these lesions is not yet fully understood, but spinal GTNI seems to have an unfavorable clinical course despite their benign histopathological features, which must be taken into account for appropriate treatment and follow-up of the patient.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Nerve Tissue / pathology. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077041.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF: Malignant transformation of intramedullary melanocytoma: case report. Neurosurgery; 2010 Sep;67(3):E867-9; discussion E869
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningeal melanocytomas are low-grade primary melanocytic tumors with benign histological features and a favorable clinical prognosis.
  • Transition from meningeal melanocytoma to primary melanoma of the central nervous system is exceptionally rare, with only 5 cases having been previously reported.
  • Two years later, the tumor recurred locally, and the patient underwent additional surgery to remove the intramedullary mass.
  • The histological findings of the tumor were consistent with an intramedullary malignant melanoma.
  • CONCLUSION: The malignant transformation of melanocytic tumors of the central nervous system may occur years after surgical treatment, and its incidence remains unknown.
  • Emphasis should be placed on the importance of careful and continued follow-up monitoring of the tumor.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Nevus, Pigmented / pathology. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657325.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • Supervised classification of the tumors did not reveal specific expression patterns representative of each WHO grade.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Deniz K, Kontas O, Tucer B, Kurtsoy A: Meningeal solitary fibrous tumor: report of a case and literature review. Folia Neuropathol; 2005;43(3):178-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal solitary fibrous tumor: report of a case and literature review.
  • Solitary fibrous tumor is a rare neoplasm that most often involves the pleura.
  • The increasing numbers of this neoplasm have also been reported to date in extrapleural sites.
  • We report a case of a twenty-four-year-old female with right frontal mass.
  • Histologically, the tumor composed of spindle cell proliferation.
  • Tumor cells were found to be positive for CD34 and CD117 with immunohistochemical studies.
  • Seventy seven cases of meningeal solitary fibrous tumor from the literature are analysed and pathological, immunohistochemical and clinical features are discussed.
  • Solitary fibrous tumor has a slight female predominance, with a male to female ratio of 1:1.5.
  • Approximately 23% of cases originate in the spine which is the most common meningeal location.
  • A differential diagnosis is important because most of the solitary fibrous tumors usually behave in a benign fashion.
  • In this study, we also showed CD117 (Kit) expression in a case of meningeal SFT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245214.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


38. Paiva-Neto MA, Tella Jr OI: Supra-orbital keyhole removal of anterior fossa and parasellar meningiomas. Arq Neuropsiquiatr; 2010 Jun;68(3):418-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maximal tumor diameter ranged from 1.6 to 6 cm.
  • All tumors were histologically benign.
  • [MeSH-major] Craniotomy / methods. Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20602048.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


39. Böthig R, Rogosch KU, Mach P, Mahn B, Burgdörfer H: [Testicular metastases as primary manifestation of malignant melanoma at known melanocytoma]. Aktuelle Urol; 2006 Mar;37(2):138-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary tumors of the testes are rare.
  • In about 15 % of the cases they are metastases of a malignant melanoma, there are about 30 reports of such cases in the literature.
  • Most of them describe findings at post-mortem, in only 4 of the previously described cases testicular metastases were the first manifestation of a melanoma.
  • The transformation of a benign, meningeal melanocytoma into a malignant melanoma has only been described once world-wide.
  • The problems in the diagnosis and therapy of this extremely rare tumor are discussed on the basis of a further patient with metastases of the testes as primary manifestation of a malignant melanoma.
  • The case history disclosed operations 10 and 3.5 year earlier for an apparently benign melanocytoma at the level of the 11th and 12th thoracic vertebrae, a local recurrence with paraparesis was known at the time of admission.
  • Sonography revealed an inhomogeneous tumor effecting the entire left testicle.
  • The correct diagnosis was made histologically.
  • CONCLUSION: In the case of a primary manifestation a correct preoperative diagnosis is unusual.
  • Radical orchiectomy is the treatment of choice for a suspected primary testicular tumor.
  • In elderly patients with unclear testicular tumors metastases from an (occult) tumor disease must be taken into consideration.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanocytes. Melanoma / secondary. Meningeal Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Testicular Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Orchiectomy. Testis / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625471.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Dave SP, Bared A, Casiano RR: Surgical outcomes and safety of transnasal endoscopic resection for anterior skull tumors. Otolaryngol Head Neck Surg; 2007 Jun;136(6):920-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes and safety of transnasal endoscopic resection for anterior skull tumors.
  • OBJECTIVE: To report the surgical outcomes and safety of transnasal endoscopic resection (TER) for anterior skull base (ASB) tumors.
  • STUDY DESIGN AND SETTING: A retrospective chart review to identify patients undergoing TER for ASB tumors at a tertiary care medical center between September 1997 and June 2006.
  • RESULTS: Nineteen patients underwent TER for ASB tumors without open craniotomy.
  • There were 17 malignant and two benign lesions.
  • One patient recurred locally, resulting in an overall local control rate of 94.7 percent for all neoplasms and 94.1 percent for malignant disease.
  • It should be noted that the tumor control rate may be premature given the small sample size and limited follow-up.
  • CONCLUSIONS: TER for ASB tumors appears to be safe in properly selected patients.
  • [MeSH-major] Carcinoma / surgery. Cranial Fossa, Anterior / surgery. Endoscopy. Esthesioneuroblastoma, Olfactory / surgery. Hemangiopericytoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Nose Neoplasms / surgery. Postoperative Complications / etiology. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547980.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Scherer K, Johnston J, Panda M: Dural based mass: malignant or benign. J Radiol Case Rep; 2009;3(11):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural based mass: malignant or benign.
  • Cerebral angiogram demonstrated a parafalcine mass supplied by the middle meningeal artery.
  • Embolization of the middle meningeal artery with craniotomy for excision of the suspected meningioma was performed.
  • Dural metastatic tumors mimicking meningiomas is an uncommon phenomenon, particularly when the primary location is the colon.
  • This paper additionally discusses the differentiation of benign dural based tumors like meningiomas from malignant findings.
  • Multiple adjunct studies can differentiate meningiomas from metastatic tumor.
  • The definitive diagnosis is based on histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Dec;33(12):1211-26 [12514791.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):317-20 [15253548.001]
  • [Cites] Acta Cytol. 1981 Sep-Oct;25(5):461-79 [7025541.001]
  • [Cites] Acta Cytol. 1981 Nov-Dec;25(6):599-610 [6947665.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Neurosurg Sci. 1987 Jan-Mar;31(1):33-6 [3625287.001]
  • [Cites] Neuroradiology. 1993;35(4):272-3 [8492892.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Feb;34(2):108-10 [7514757.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):241-5 [12480230.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):193-9 [12187955.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):880-7 [11419971.001]
  • [Cites] Australas Radiol. 2005 Dec;49(6):497-500 [16351616.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):135-7 [9213059.001]
  • [Cites] Neurologist. 2006 Jan;12(1):48-52 [16547447.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] Neurochirurgie. 1999 May;45(2):160-3 [10448659.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):552-8 [9761048.001]
  • (PMID = 22470624.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303278
  • [Keywords] NOTNLM ; Dural based mass / meningioma / metastatic dural based lesions
  •  go-up   go-down


42. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP: A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics; 2006;7:539
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors.
  • BACKGROUND: The development of effective frameworks that permit an accurate diagnosis of tumors, especially in their early stages, remains a grand challenge in the field of bioinformatics.
  • Our approach uses statistical learning techniques applied to multiple antigen tumor antigen markers utilizing the immune system as a very sensitive marker of molecular pathological processes.
  • For validation purposes we choose the intracranial meningioma tumors as model system since they occur very frequently, are mostly benign, and are genetically stable.
  • Detailed analysis revealed that prediction performs particularly well on low-grade (WHO I) tumors, consistent with our goal of early stage tumor detection.
  • For these tumors the best classification result with a specificity of 97.5%, a sensitivity of 91.3%, an accuracy of 95.6%, and an area under the ROC curve of 0.971 was achieved using a set of 12 antigen markers only.
  • Remarkably, our study proves that the inclusion of non-specific antigens, detected not only in tumor but also in normal sera, increases the performance significantly, since non-specific antigens contribute additional diagnostic information.
  • CONCLUSION: Our approach offers the possibility to screen members of risk groups as a matter of routine such that tumors hopefully can be diagnosed immediately after their genesis.
  • [MeSH-major] Algorithms. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / immunology. Meningioma / diagnosis. Meningioma / immunology
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Gene Expression Profiling / methods. Humans. Immunoassay / methods. Pattern Recognition, Automated / methods. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Meningioma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6 [12601173.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3034-44 [15226172.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Urol. 2005 May;173(5):1456-62 [15821460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6 [15983380.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):736-8 [16915260.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 17184519.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1769403
  •  go-up   go-down


43. Nasseri K, Mills JR: Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005. Cancer Detect Prev; 2009;32(5-6):363-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.
  • The purpose of this study was to compare the epidemiology of primary brain tumors in this ethnic population with the non-Hispanic, non-Middle Eastern White (NHNMW) in California.
  • Data for 683 cases of primary brain tumors (429 benign, 238 malignant, 16 uncertain) in the ME and 15,589 cases (8352 benign, 6812 malignant, 425 uncertain) in the NHNMW were available for this study.
  • RESULTS: ME patients were significantly (p < 0.05) younger and their age-adjusted incidence rates per 100,000 for benign tumors of 10.0 in men and 17.6 in women were higher than similar rates of 7.3 and 10.6 in the NHNMW group (p < 0.05).
  • Rates for malignant tumors were similar.
  • Also increased were benign tumors of the pituitary and pineal glands.
  • The overall mortality in patients with benign tumors was significantly lower than malignant tumors.
  • CONCLUSIONS: This study presents a significantly high incidence of benign meningioma in the ME population in California.
  • This may be due to higher susceptibility or exposure of this ethnic group to the risk factor(s) for this neoplasm.
  • Considering the reported causal association of benign meningioma with childhood radiation exposure from Israel, exposure to this risk factor in this ethnic group needs to be evaluated in future studies.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. California / epidemiology. Child. Child, Preschool. Continental Population Groups / statistics & numerical data. European Continental Ancestry Group / statistics & numerical data. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / ethnology. Meningioma / epidemiology. Meningioma / ethnology. Middle Aged. Middle East / ethnology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):470-80 [18206397.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):424-9 [18023539.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2798-806 [16288487.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):405-11 [18159978.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):203-8 [12787727.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Br J Surg. 1977 Jul;64(7):457-9 [922301.001]
  • [Cites] J Carcinog. 2005 Nov 10;4:21 [16283945.001]
  • [Cites] Calif Med. 1949 Mar;70(3):189-93 [18112454.001]
  • (PMID = 19588542.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA103457; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / CA / R03 CA103457-02; United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / R03 CA103457; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-54404; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140088; NLM/ PMC2785228
  •  go-up   go-down


44. Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology; 2005;25(3):120-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case-control study on the use of cellular and cordless telephones and the risk for brain tumors.
  • We report the results for benign brain tumors with data from 413 cases (89% response rate), 305 with meningioma, 84 with acoustic neuroma, 24 with other types and 692 controls (84% response rate).
  • [MeSH-major] Cell Phones / utilization. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15956809.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


45. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Here, we analyzed the GEP of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, as confirmed through the analysis of 172 patients.
  • Additionally three normal meningeal samples were also studied.
  • Overall, our results show a clear association between the clinically relevant cytogenetic subgroups of meningiomas including diploid tumors (n = 18), isolated -22/22q- (n = 12), del(1p36) alone (n = 4) and complex karyotypes associated with del(1p36) and/or -14q (n = 13) and their GEP.
  • Accordingly, based on the expression of 85 genes (40 of which were coded in the altered chromosomes used for patient stratification) the cytogenetic class of the tumor could be predicted with an error of <1%, a clear association being found between the GEP and patient outcome (P = 0.03) but not tumor histopathology.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


46. Bikmaz K, Mrak R, Al-Mefty O: Management of bone-invasive, hyperostotic sphenoid wing meningiomas. J Neurosurg; 2007 Nov;107(5):905-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The hyperostosis frequently associated with sphenoid wing meningiomas is actual invasion of bone by the tumor.
  • The intracranial portion of the tumor is usually thin with en plaque spread, and the tumor tends to invade the orbit through the superior orbital fissure.
  • Chromosome analysis was performed in all tumors resected since 2001 (seven cases).
  • These lesions are generally histologically benign.
  • [MeSH-major] Hyperostosis / pathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Invasiveness / pathology. Orbit / pathology
  • [MeSH-minor] Adult. Aged. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977259.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


47. Okuducu AF, Zils U, Michaelis SA, Mawrin C, von Deimling A: Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer; 2006 Sep 15;107(6):1365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The transcription factor avian erythroblastosis virus E26 (V-Ets) oncogene homolog 1 (Ets-1) is involved in tumor development and progression through the transcriptional regulation of several matrix-degrading enzyme systems, including matrix metalloproteinases (MMPs).
  • To determine the biologic significance of Ets-1 in the progression of benign meningiomas, the authors investigated the expressions of Ets-1 and its target genes MMP-2 and MMP-9 in primary and recurrent, Grade 1 meningiomas.
  • METHODS: The expression levels of Ets-1, MMP-2, and MMP-9 were examined by immunohistochemistry in 70 Grade 1 meningiomas, including 36 primary tumors without recurrence after 5 years of follow-up and 17 pairs of primary tumors and subsequent recurrences.
  • [MeSH-major] Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 9 / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Proto-Oncogene Protein c-ets-1 / biosynthesis
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Risk Factors. World Health Organization

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16894529.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


48. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


49. Johnson WD, Loredo LN, Slater JD: Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus; 2008;24(5):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors.
  • Historically, radiation therapy has been used extensively in the treatment of malignant and aggressive intracranial tumors, and the importance of its role has been repeatedly verified by prolonged patient survival rates and increased tumor control.
  • As more modern capabilities are employed in surgery and radiotherapy, attention is being directed to the utility of radiation as either primary or secondary treatment of benign tumors.
  • Specifically, primary treatment encompasses irradiation of small benign tumors without biopsy confirmation of tumor type; secondary treatment involves postoperative radiation therapy, with the possibility that less-aggressive tumor resection may be performed in areas that have a higher probability of resultant neurological deficit.
  • This article provides an overview of factors to consider in the use of radiation therapy and reviews the relationships between radiation and surgery, notably the unique complementary role each plays in the treatment of benign intracranial tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Cranial Irradiation
  • [MeSH-minor] Adenoma / radiotherapy. Adenoma / surgery. Combined Modality Therapy. Dose Fractionation. Elementary Particles / therapeutic use. Humans. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neurilemmoma / radiotherapy. Neurilemmoma / ultrasonography. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Radioisotopes / therapeutic use. Radiosurgery / instrumentation. Radiosurgery / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447741.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes
  • [Number-of-references] 55
  •  go-up   go-down


50. Weber DC, Lovblad KO, Rogers L: New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Curr Opin Neurol; 2010 Dec;23(6):563-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New prospective trials have been initiated, and it is foreseen that American Society of Clinical Oncology evidence-level II will be soon available for this brain tumor.
  • Apparent diffusion coefficient values on MRI observed with grade II and grade III meningiomas are significantly decreased when compared to benign tumors.
  • [F]fluorodeoxyglucose PET may also predict tumor grade and tumor recurrence.
  • [MeSH-major] Diagnostic Imaging / trends. Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiotherapy. Meningioma / pathology. Meningioma / radiotherapy

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885321.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


51. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
  • Meningiomas are, in general, slowly growing benign tumors attached to the dura mater and composed of neoplastic meningothelial (arachnoidal) cells.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • The lysosomal cysteine proteinases, cathepsins B and L, have been associated with tumor invasiveness and the aim of this study was therefore to evaluate them, together with their endogenous inhibitors stefin B and cystatin C, as potential markers for the aggressiveness of meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The protein levels of cathepsins B (p=0.050) and L (p=0.019) were found to be significantly higher in atypical than in benign meningiomas.
  • Protein and mRNA levels of stefin B (p= 0.007), but not cystatin C, were significantly lower in atypical compared with benign meningiomas.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / antagonists & inhibitors. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cathepsin L. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cystatin B. Cystatin C. Disease Progression. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


52. Ahmadi SA, Samadi N: Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas. Ann Saudi Med; 2006 Jan-Feb;26(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparing nonrecurrent, recurrent, atypical and malignant meningiomas we studied the value of the routine applicability of the AgNOR count in the prognostication of this tumor.
  • Eighty-one cases were selected and arranged in six groups according to clinical data and grading: 14 benign non-recurrent meningiomas; 14 primary benign recurrent meningiomas and their subsequent benign recurrences; 14 atypical; 11 malignant and 14 spinal meningiomas.
  • RESULTS: There was a proportionate increase of AgNOR dots with increasing tumor grade.
  • There was a significant difference between benign non-recurrenttumors versus benign recurrent (P<0.0001) and atypical or malignant (P<0.0001) tumors.
  • A difference was also noted between the recurring tumors versus malignant ones (P = 0.002) but no significant difference was seen between recurrent and atypical; atypical and malignant; intracranial and intraspinal; and primary of recurring meningiomas with their subsequent recurrences.
  • A mean AgNOR count of <2.3 could separate benign tumors from atypical or malignant meningiomas with 93% specificity; and 93% of tumors with benign histology had no recurrence potential if their mean AgNOR count was less than 1.8.
  • CONCLUSION: This study indicates that in meningioma, the AgNOR count has a good correlation with tumor grading and recurrence, which may aid pathologists and clinicians in predicting tumor behavior.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Nucleolus Organizer Region / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521873.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


53. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • The tumors were graded according to the World Health Organization classification.
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurofibromatosis 2 / immunology. Neurofibromatosis 2 / metabolism. PTEN Phosphohydrolase / analysis. Recurrence. Risk Assessment. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


54. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I: Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest; 2009 Jul;27(6):691-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas represent 30% of primary cranial tumors, are mostly benign, and prevail in the second half of life.
  • Tumor therapy requires information about molecular alterations, thus we studied expression of ErbB receptor and ligand genes by real-time RT-PCR in different meningioma grades.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, erbB. Intercellular Signaling Peptides and Proteins / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amphiregulin. Betacellulin. EGF Family of Proteins. Epidermal Growth Factor / genetics. Epigen. Female. Glycoproteins / genetics. Heparin-binding EGF-like Growth Factor. Humans. Ligands. Male. Middle Aged. Neoplasm Staging. Neuregulins / genetics. Polymerase Chain Reaction. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Receptor, ErbB-4. Transforming Growth Factor alpha / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440932.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / BTC protein, human; 0 / Betacellulin; 0 / EGF Family of Proteins; 0 / EPGN protein, human; 0 / Epigen; 0 / Glycoproteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / Neuregulins; 0 / RNA, Messenger; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


55. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


56. Drakos SS, Anifantaki F, Zarros A, Liapi C: The role of folate metabolism-related gene polymorphisms in the development of meningiomas. Cancer Genomics Proteomics; 2010 Mar-Apr;7(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are (usually) slow-growing benign tumors, and several factors have been implicated in their development.
  • The complex genetic background supporting the pathogenesis of meningiomas includes a large number of mutations and polymorphisms that might be actively involved in tumor development, progression and recurrence.
  • [MeSH-major] Folic Acid / metabolism. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Polymorphism, Single Nucleotide / genetics

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335525.001).
  • [ISSN] 1790-6245
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Number-of-references] 38
  •  go-up   go-down


57. Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA: CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat; 2005 Oct;4(5):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.
  • Limited data exists for the use of radiosurgery for benign extracranial tumors.
  • The purpose of this study was to evaluate the feasibility, toxicity, and local control of patients with benign extracranial lesions treated with the CyberKnife Frameless Radiosurgery System.
  • From September 2001 thru January 2004, 59 benign tumors in 44 patients were treated using the CyberKnife a frameless image-guided radiosurgery system.
  • Of these tumors, there were 21 neurofibromas, ten schwannomas, eight meningiomas, eight hemangioblastomas, seven paragangliomas, two hemangiopericytomas, one pseudotumor, one ependymoma, and one arteriovenous malformation (AVM).
  • The anatomic locations of these tumors were spinal (25 cervical, four thoracic, 14 lumbar, and two sacral), neck (eight), orbital (three), brainstem (one), and foramen magnum (one).
  • The median tumor dose delivered was 16.0 Gy to the 80% isodose line (range 10-31 Gy).
  • The median tumor volume was 4.3 cc (range 0.14-98.6 cc).
  • This study suggests that CyberKnife Radiosurgery is a safe and efficacious treatment modality for benign tumors, even for those patients with recurrent previously irradiated lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Safety. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173828.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Elguezabal A, Díaz ML, Landeyro J, Gené M, Boutayeb L, Escosa M, Sirvent JJ: [Solid-cystic supratentorial hemangioblastoma affecting the falx cerebri. Report of a case]. Neurocirugia (Astur); 2010 Oct;21(5):401-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solid-cystic supratentorial hemangioblastoma affecting the falx cerebri. Report of a case].
  • [Transliterated title] Hemangioblastoma sólido-quístico supratentorial afectando la hoz del cerebro. Presentación de un caso.
  • INTRODUCTION: hemangioblastomas are benign neoplasias that are originated in the central nervous system and constitute between 1.5-2.5% of intracranial tumors.
  • Meningeal involvement is infrequent.
  • In 30% of the cases, these tumors are associated with von Hippel Lindau syndrome (VHL).
  • CONCLUSION: the preoperative diagnosis of these neoplasms is difficult because the clinical suspicion is low in supratentorial location.
  • Imaging techniques are useful but definitive diagnosis is made through pathologic examination.
  • The use of immunohistochemical techniques is helpful for the differential diagnosis with lesions that are more common in this region.
  • The importance of a correct diagnosis of these histologically benign tumors, lies on the possible association with VHL syndrome and its complications.
  • [MeSH-major] Dura Mater. Hemangioblastoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / pathology

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042692.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


59. Nakasu S, Fukami T, Nakajima M, Watanabe K, Ichikawa M, Matsuda M: Growth pattern changes of meningiomas: long-term analysis. Neurosurgery; 2005 May;56(5):946-55; discussion 946-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Although tumors are generally expected to grow exponentially, it is not known whether meningiomas retain a constant growth rate or not because of the lack of long-term follow-up.
  • Seven patients (including two neurofibromatosis cases) had incidental tumors.
  • Another 13 patients with symptomatic tumors were followed after surgery.
  • Two calcified tumors did not grow.
  • Although the other benign tumors grew exponentially or linearly, their tumor volume doubling times in the initial phase were shorter than those in the later phase in most cases.
  • This was supported by the observation that in two patients, the tumor growth pattern changed from exponential to linear and from linear to no growth with progression of calcification.
  • Conversely, benign meningiomas revealed exponential, linear, or no growth.
  • [MeSH-major] Cell Division / physiology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854242.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A: Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol; 2009 Dec;95(3):413-419
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.
  • The aim of this article is to evaluate and assess the impact of various factors on quality of life (QOL) in adult patients with primary brain tumors seen consecutively in routine neurooncology practice.
  • Two hundred and fifty-seven adult patients, after undergoing surgical intervention and histologically proven primary brain neoplasms were registered in the NeuroOncology Clinic at our centre during 1 full calendar year.
  • In the present analysis, QOL scores before starting adjuvant treatment were measured and impact of patient and tumor related factors were analyzed.
  • Baseline global QOL data of all patients (available in 243) was relatively low including in all histological tumor types.
  • Domains of future uncertainty, visual disorder, motor deficit, communication deficit, headache, seizures and drowsiness scores were 19.6, 18.2, 28.5, 30.7, 21, 31.8 and 16 (lower values better), respectively.
  • Patients with lower performance status (KPS < 70) had a lower global QOL (KPS >or= 80 vs. <or= 70; 37 vs. 67; p = 0.001) including in all histological types of high-grade gliomas (HGG) (p = 0.005), low-grade gliomas (LGG) (p = 0.04) and benign tumors (p = <0.001).
  • Tumor type is an important patient related factor that influences baseline global scores (LGG vs. HGG 62 and 52; p = 0.015).
  • Type of surgery (biopsy/complete excision) (p = 0.284) and site of tumor (p = 0.309) did not show any impact on QOL score.
  • Patients with malignant tumors and poor performance status had significantly lower QOL scores even before starting adjuvant treatment.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Outpatient Clinics, Hospital. Quality of Life
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / therapy. Adolescent. Adult. Educational Status. Female. Health Status. Humans. India. Karnofsky Performance Status. Male. Meningeal Neoplasms / physiopathology. Meningeal Neoplasms / therapy. Middle Aged. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prospective Studies. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1824-31 [12204663.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):103-10 [19255726.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12 ):937-44 [16321761.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Cancer Res Ther. 2006 Oct-Dec;2(4):166-70 [17998699.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] BMC Cancer. 2007 Jan 25;7:18 [17254350.001]
  • (PMID = 19548070.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Montano N, Doglietto F, Lauriola L, Signorelli F, Pallini R: Solitary fibrous tumour of the IV ventricle. Br J Neurosurg; 2010 Aug;24(4):495-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the IV ventricle.
  • BACKGROUND: Solitary Fibrous Tumour (SFT) is a rare tumour occurring mainly in the pleural cavity, with less than 100 cases reported in the Central Nervous System, where it typically presents as a meningeal-based lesion.
  • We describe the case of a SFT located in the fourth ventricle and briefly review the pertinent literature.
  • CONCLUSION: Although uncommon, SFT should always be included in the differential diagnosis of intraventricular tumours.
  • SFTs of the fourth ventricle are usually benign tumours.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Solitary Fibrous Tumors / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726760.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Grujicić M, Vucković N, Vuleković P: [Morphological characteristics of meningiomas]. Med Pregl; 2010 Mar-Apr;63(3-4):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Meningiomas are common intracranial neoplasms which originate from the soft meninges, precisely from meningeal arachnoidal cells.
  • It included 490 consecutive patients of both sexes with diagnosed intracranial tumors and undergoing surgical treatment at the Neurosurgery Clinic of the Clinical Center of Vojvodina.
  • Out of 490 patients with diagnosed intracranial tumors, 137 (27.96%) were diagnosed to have meningiomas.
  • In regard to other histological types of intracranial tumors, meningiomas were more frequent in females (36.3%).
  • The commonest histological types of meningiomas were benign meningiomas (93.4%).
  • Malignant histological types of meningiomas were more common in males (83.3%), whereas benign histological types were more common in females (64.1%).
  • The tumor is located in the left frontal region.
  • On histology it is benign, transitional type of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053467.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


63. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other 19 tumors showed partial disruption of the arachnoid membrane.
  • The degree of arachnoid disruption correlated with the tumor grade, perifocal edema, pial blood supply on angiography, and tumor size.
  • The existence of brain invasion correlated with the tumor grade and partially with tumor size.
  • In case of invasive tumor, GFAP-positive cells were found deep in the tumor, usually in contact with blood vessels.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • A pia mater-like structure covered the tumor surface in both cases.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure
  • [MeSH-minor] Amyloid beta-Protein Precursor / analysis. Arachnoid / ultrastructure. Brain Edema / etiology. Collagen Type IV / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neurofilament Proteins / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


64. Kalamarides M, Peyre M, Giovannini M: Meningioma mouse models. J Neurooncol; 2010 Sep;99(3):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery.
  • As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice.
  • Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported.
  • Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors.
  • These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis.
  • [MeSH-major] Disease Models, Animal. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):197-201 [11266526.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):545-50 [2477514.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60 [17415213.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Proc Soc Exp Biol Med. 1977 May;155(1):85-8 [193127.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] J Neurosurg. 1995 May;82(5):864-73 [7714613.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):130-5; discussion 135-6 [9442514.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Surg Neurol. 2001 May;55(5):275-83 [11516467.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):328-34 [11599449.001]
  • [Cites] Toxicol Pathol. 2007 Oct;35(6):780-7 [17943659.001]
  • [Cites] J Neurosci. 1997 Apr 1;17(7):2376-82 [9065498.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):584-7 [3559725.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] Clin Neuropathol. 1994 Mar-Apr;13(2):82-7 [8205731.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] Exp Toxicol Pathol. 2008 Aug;60(4-5):247-51 [18524558.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):720-4 [7501018.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Brain Tumor Pathol. 1997;14 (2):139-43 [15726793.001]
  • [Cites] Cell. 1987 Nov 6;51(3):503-12 [2822260.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6090-3 [7954452.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):295-307; discussion 307 [18261772.001]
  • [Cites] Cell Prolif. 2005 Feb;38(1):3-12 [15679862.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):202-14 [10669008.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • (PMID = 20734219.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


65. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK: Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg; 2005 Jan;102 Suppl:143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases.
  • Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Exophthalmos / etiology. Meningeal Neoplasms / surgery. Meningioma / surgery. Optic Nerve Glioma / surgery. Optic Nerve Neoplasms / surgery. Postoperative Complications. Radiosurgery / instrumentation. Vision Disorders / etiology
  • [MeSH-minor] Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Radiation Dosage. Tumor Burden / radiation effects. Visual Acuity / physiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662798.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM: Tissue transgluaminase 2 expression in meningiomas. J Neurooncol; 2008 Nov;90(2):125-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are common intracranial tumors that occur in extra-axial locations, most often over the cerebral convexities or along the skull-base.
  • Although often histologically benign these tumors frequently present challenging clinical problems.
  • Primary clinical management of patients with symptomatic tumors is surgical resection.
  • Radiation treatment may arrest growth or delay recurrence of these tumors, however, meningioma cells are generally resistant to apoptosis after treatment with radiation.
  • Tumor cells are known to alter their expression of proteins that interact in the ECM to provide signals important in tumor progression.
  • One such protein, fibronectin, is expressed in elevated levels in the ECM in a number of tumors including meningiomas.
  • KCC009 treatment promoted apoptosis and enhanced radiation sensitivity both in cultured IOMM-Lee meningioma cells and in meningioma tumor explants.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. Putrescine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):825-38 [10684262.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2563-73 [17099729.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2989-3000 [11686302.001]
  • [Cites] Breast Cancer Res Treat. 2002 Feb;71(3):237-47 [12002342.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):302-6 [12073047.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Sep;2(3):257-77 [12188911.001]
  • [Cites] Trends Biochem Sci. 2002 Oct;27(10):534-9 [12368090.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1652-4; author reply 1654 [12419794.001]
  • [Cites] Biochem J. 2002 Dec 1;368(Pt 2):377-96 [12366374.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):140-56 [12563291.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Apr;28(4):428-35 [12654631.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42604-14 [12732629.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] Int J Radiat Biol. 2003 Sep;79(9):709-20 [14703944.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):95-102 [15102436.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Acta Neuropathol. 1985;66(3):245-52 [3893018.001]
  • [Cites] J Neuropathol Exp Neurol. 1986 May;45(3):285-303 [3083053.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Science. 1994 Jun 10;264(5165):1593-6 [7911253.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):37-47 [7806590.001]
  • [Cites] Science. 1995 Apr 14;268(5208):233-9 [7716514.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2783-93 [9184223.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4406-18 [9234699.001]
  • [Cites] Curr Opin Cell Biol. 1997 Oct;9(5):701-6 [9330874.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8068-76 [15585642.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Chem Biol. 2005 Apr;12(4):469-75 [15850984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):32-7 [15850899.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1269-75 [15979576.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1293-302 [16170020.001]
  • [Cites] J Neurochem. 2000 Nov;75(5):1951-61 [11032884.001]
  • (PMID = 18587533.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK063158; United States / NIDDK NIH HHS / DK / R01 DK63158
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Fibronectins; 0 / Isoxazoles; 0 / KCC 009; 10028-17-8 / Tritium; EC 2.3.2.- / transglutaminase 2; EC 2.3.2.13 / Transglutaminases; EC 3.6.1.- / GTP-Binding Proteins; V10TVZ52E4 / Putrescine
  • [Other-IDs] NLM/ NIHMS488704; NLM/ PMC3732188
  •  go-up   go-down


67. Adams H, Went P, Tolnay M, Sartorius G, Singer G: [Meningothelial meningioma in a mature cystic teratoma of the ovary]. Pathologe; 2007 Jul;28(4):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Meningotheliomatöses Meningeom in einem reifen zystischen Teratom des Ovars.
  • Mature teratomas belong to the group of germ cell tumors of the ovary.
  • They account for 27-44% of all ovarian neoplasms and up to 58% of all benign tumors of the ovary.
  • In mature as well as in immature teratomas, secondary tumors originating from the three embryonic tissue components may be found.
  • These tumors can show benign or malignant behavior.
  • We report the case of a meningothelial meningioma, found within a mature teratoma of a 32 year old female.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology


68. El-Khashab M, Koral K, Bowers DC, Johnson-Welch S, Swift D, Nejat F: Intermediate grade meningeal melanocytoma of cervical spine. Childs Nerv Syst; 2009 Apr;25(4):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermediate grade meningeal melanocytoma of cervical spine.
  • BACKGROUND: Meningeal melanocytoma is a rare, benign melanotic tumor of the leptomeninges, which occurs anywhere in the cranial or spinal regions but most commonly in supratentorial and thoracic spine regions.
  • The literature on this entity consists of case reports; therefore, there is no agreement on the most effective therapy of this tumor, although total excision seems to be the best therapeutic option.
  • CASE HISTORY: We report a 17-year-old girl with intermediate grade meningeal melanocytoma involving the C6 nerve root with spinal cord compression resulted in progressive tetraparesis.
  • The tumor was removed subtotally through cervical laminotomy followed by rapid improvement of most neurological deficits.
  • This tumor was unusual because of its very hyperintense homogenous signal on T1-weighted images, invasion of the arachnoid membrane, and extension into the neural foramina.
  • Black dots on the surface of the cord were thought to represent an organized blood clot until the frozen section suggested a melanocytic tumor.
  • DISCUSSION: We discuss the distinction of meningeal melanocytoma from other melanocytic tumors of the leptomeninges.
  • CONCLUSION: Melanocytic tumors should be considered in the differential diagnosis when a hyperintense lesion of the leptomeninges is identified on T1-weighted images or a very dark mass similar to charcoal or organized hematoma is found in the surgical field.
  • The best management is complete tumor resection, but radiotherapy is reserved in cases of subtotal resection and multiple lesions.
  • Locally aggressive nature of tumor and possibility of recurrence warrant regular follow-up.
  • [MeSH-major] Cervical Vertebrae. Medulloblastoma / pathology. Meningeal Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Meninges / pathology. Meninges / surgery. Spinal Cord / pathology. Spinal Cord / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2003 Mar;59(3):200-10 [12681556.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):287-90 [15029918.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):958-61 [1436425.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):315-6 [1902034.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):55-60 [8770250.001]
  • [Cites] J Neurosurg Spine. 2007 May;6(5):451-4 [17542513.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):945-8 [1436422.001]
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):556-61 [16491422.001]
  • [Cites] J Neurosurg. 1998 May;88(5):890-4 [9576259.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):180-2 [9010539.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):225-31 [11599841.001]
  • (PMID = 19139906.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Kang SG, Yoo DS, Cho KS, Kim DS, Chang ED, Huh PW, Kim MC: Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy-Walker cyst in a patient with neurocutaneous melanosis. Case report. J Neurosurg; 2006 Mar;104(3):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy-Walker cyst in a patient with neurocutaneous melanosis. Case report.
  • Primary intracranial melanocytic and dermoid tumors are also benign congenital lesions that usually arise from the leptomeninges and are formed by the inclusion of cutaneous ectoderm at the time of neural tube closure.
  • The authors describe a patient with coexisting intracranial meningeal melanocytoma, NCM with Dandy-Walker malformation, and intraventricular dermoid tumor.
  • [MeSH-major] Dandy-Walker Syndrome / complications. Dermoid Cyst / pathology. Melanoma / pathology. Melanosis / complications. Meningeal Neoplasms / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Neurocutaneous melanosis.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572661.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T: Early malignant transformation of a petroclival meningothelial meningioma. Neurosurg Rev; 2009 Oct;32(4):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early malignant transformation of a petroclival meningothelial meningioma.
  • The tumor was subtotally removed and was diagnosed to be a meningothelial meningioma.
  • Seven months after surgery, a recurrence of the tumor was confirmed.
  • The diagnosis of this recurrent tumor was an atypical meningioma.
  • The MIB-1 index and the percent of p53 protein-positive cells in the primary tumor were 4.6% and 35.4%, respectively, whereas those of the recurrent tumor were 34.7% and 33.1%, respectively.
  • A chromosomal DNA copy number loss was observed on 1p, 6q, 10, 14q, and -22q detected in both the primary and the recurrent tumors.
  • These results suggest that the present case had a potentially malignant tumor in the early stage, although it had the histological features of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Cerebral Angiography. DNA / genetics. Female. Gait Disorders, Neurologic. Gene Dosage. Hearing Disorders / etiology. Humans. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Meningeal Arteries / surgery. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):214-22 [12913843.001]
  • [Cites] Cell. 1998 Oct 2;95(1):5-8 [9778240.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):29-33 [9426052.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):148-51 [14734228.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1313-8 [1886708.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):857-61 [4056899.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2386-92 [8485725.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75 [10736068.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):354-7 [8314321.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Neuropathol Appl Neurobiol. 1995 Apr;21(2):136-42 [7609844.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):398-404 [17695396.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):62-7 [11333301.001]
  • [Cites] J Med Genet. 2006 Mar;43(3):285-7 [15980114.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 19533187.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


71. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down


72. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M: Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol; 2008 Jan;18(1):62-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity.
  • Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior.
  • Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas.
  • Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon.
  • Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Neurofibromin 2 / genetics
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Drug Screening Assays, Antitumor / methods. Female. Gene Deletion. Genetic Predisposition to Disease / genetics. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Mice. Mice, Knockout. Mice, Mutant Strains. Mutation / genetics. Neoplasm Invasiveness / genetics. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / physiopathology


73. Kao HW, Chen CY, Hsueh CJ, Lo CP, Juan CJ, Chang WC, Huang GS: Typical Meningioma with Atypical MR Imaging Features Masquerading Malignancy. A Case Report. Neuroradiol J; 2007 Oct 31;20(5):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common extraaxial tumors of intracranial neoplasms.
  • They are usually benign with characteristic pathologic and imaging features.
  • Unusual imaging features such as large meningeal cysts, ring enhancement, and various metaplastic changes can be particularly misleading.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24299943.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Zhi L, Bing L, Yang L, Bo-ning L, Quan H: Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature. Pathol Res Pract; 2009;205(8):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas usually present as benign tumors corresponding to WHO grade I.
  • The tumor exhibits a marked peritumoral cyst, with contrast enhancement on magnetic resonance imaging (MRI) in accordance with type 2 of Zee's classification of cystic meningioma.
  • Histologically, the tumor displays a classical perivascular pseudopapillary pattern with focal necrosis and subarachnoid space dissemination.
  • Tumor cells are diffusely positive for epithelial membrane antigen (EMA) and vimentin, but lack immunoreactivity for cytokeratin (CK) and glial fibrillary acidic protein (GFAP).
  • MIB-1 labeling is high, accounting for 5% of tumor focally.
  • A diagnosis of primary intraventricular cystic papillary meningioma with subarachnoid space dissemination (WHO grade III) was made.
  • In addition, the biological behavior and the clinical outcome of this tumor are also discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Magnetic Resonance Imaging. Mucin-1 / metabolism. Neoplasm Staging. Treatment Outcome. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307065.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


75. Stremenová J, Mares V, Lisá V, Hilser M, Krepela E, Vanicková Z, Syrucek M, Soula O, Sedo A: Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol; 2010 Feb;36(2):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are tumors derived from arachnoid cap cells that represent approximately 30% of all intracranial tumors.
  • DPP-IV-like enzymatic activity, including all enzymatically-active DASH molecules, was found in all 18 benign meningiomas WHO grade I and IV atypical meningiomas WHO grade II by continuous rate fluorimetric assay in tissue homogenates and catalytic enzyme histochemistry in situ.
  • Expression of CXCR4, the receptor of pro-proliferative chemokine stromal cell-derived factor-1alpha (SDF-1alpha), DPP-IV substrate, was found in all tumors, suggesting higher values in atypical grade II samples.
  • In addition, the study suggests an increase of DPP-IV-like enzymatic activity in these tumors of WHO grade II.
  • [MeSH-major] Dipeptidases / metabolism. Dipeptidyl Peptidase 4 / metabolism. Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / metabolism. Meningeal Neoplasms / enzymology. Meningioma / enzymology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Gelatinases / genetics. Gelatinases / metabolism. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Isoenzymes / genetics. Isoenzymes / metabolism. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Serine Endopeptidases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043068.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / RNA, Messenger; EC 3.4.13.- / Dipeptidases; EC 3.4.14.- / DPP9 protein, human; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.5 / DPP8 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


76. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J: WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol; 2009 Dec;95(3):367-375
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas represent one of the largest subgroups of intracranial tumors.
  • They are generally benign, but may show a histological progression to malignancy.
  • [MeSH-major] Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningioma / mortality. Meningioma / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Cause of Death. Databases, Factual. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies


77. Tlachacova D, Schmitt M, Novotny J Jr, Novotny J, Majali M, Liscak R: A comparison of the gamma knife model C and the automatic positioning system with Leksell model B. J Neurosurg; 2005 Jan;102 Suppl:25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were obtained in 463 patients treated with the B model and 518 patients treated with the C model.
  • Data were analyzed in patients in whom the following diagnoses had been made: vestibular schwannoma, pituitary adenoma, meningioma, solitary metastasis, and other benign and malignant solitary tumors.
  • [MeSH-major] Adenoma / surgery. Automation / instrumentation. Brain Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Pituitary Neoplasms / surgery. Radiosurgery / instrumentation


78. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery; 2009 Feb;64(2 Suppl):A7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients.
  • OBJECTIVE: To present initial, short-term results obtained with an image-guided radiosurgery apparatus (CyberKnife; Accuray, Inc., Sunnyvale, CA) in a series of 199 benign intracranial meningiomas.
  • All patients were either symptomatic and/or harboring growing tumors.
  • Ninety-nine tumors involved the cavernous sinus; 28 were in the posterior fossa, petrous bone, or clivus; and 29 were in contact with anterior optic pathways.
  • Twenty-two tumors involved the convexity, and 21 involved the falx or tentorium.
  • Tumor volumes varied from 0.1 to 64 mL (mean, 7.5 mL) and radiation doses ranged from 12 to 25 Gy (mean, 18.5 Gy).
  • In 150 patients with lesions larger than 8 mL and/or with tumors situated close to critical structures, the dose was delivered in 2 to 5 daily fractions.
  • The tumor volume decreased in 36 patients, was unchanged in 148 patients, and increased in 7 patients.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165077.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Modha A, Gutin PH: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery; 2005 Sep;57(3):538-50; discussion 538-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
  • Atypical and anaplastic meningiomas are uncommon tumors with a poorer prognosis than benign meningiomas.
  • We reviewed the current literature and attempted to integrate and summarize available information to determine a logical approach to these tumors.
  • Both tumors are rare and are often integrated with benign meningiomas when treatments are evaluated.
  • Malignant progression with accumulation of mutations in a benign meningioma can result in an atypical and/or anaplastic meningioma.
  • Both tumors are difficult to manage and have high recurrence and poor survival rates.
  • The extent of tumor resection and histological grade are the key determinants for recurrence.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy
  • [MeSH-minor] Algorithms. Anaplasia / diagnosis. Anaplasia / metabolism. Anaplasia / therapy. Disease Progression. Drug Therapy / methods. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging. Radiosurgery. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145534.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Number-of-references] 65
  •  go-up   go-down


80. Fulkerson DH, Horner TG, Hattab EM: Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature. Clin Neurol Neurosurg; 2008 Apr;110(4):416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature.
  • Metastasis from a histologically "benign" meningioma is a rare, but well-documented event.
  • The tumors in these reports had a frankly malignant histology or were associated with surgical manipulation and recurrence of the primary lesion.
  • In this report, the authors present a rare case of the concurrent presentation of a histologically benign intraventricular meningioma and a solitary lung lesion which proved to be metastatic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningioma / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Humans. Ki-67 Antigen / analysis. Lung / pathology. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Receptors, Progesterone / analysis


81. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N: Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer; 2010;10:79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ZIC family genes in meningiomas and other brain tumors.
  • BACKGROUND: Zic zinc finger proteins are present in the developing rodent meninges and are required for cell proliferation and differentiation of meningeal progenitors.
  • METHODS: We examined the mRNA and protein expression of human ZIC1, ZIC2, ZIC3, ZIC4 and ZIC5 genes in meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and immunostaining.
  • The expression level of ZIC1 in public microarray data was greater in meningiomas classified as World Health Organization Grade II (atypical) than those classified as Grade I (benign).
  • In normal meninges, ZIC-like immunoreactivities were detected in vimentin-expressing arachnoid cells both in human and mouse.
  • The pattern of ZIC expression in both of these tumor types may reflect the properties of the tissues from which the tumors are derived.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Meningioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):669-84 [17490632.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):83-91 [11015565.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):218-25 [11756505.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1985-7 [12499499.001]
  • [Cites] Mol Cell Neurosci. 2004 Jun;26(2):205-21 [15207846.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):377-83 [8542595.001]
  • [Cites] Clin Genet. 2005 Apr;67(4):290-6 [15733262.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Nucleic Acids Res. 2007;35(7):e51 [17344319.001]
  • [Cites] J Neuroimmunol. 2008 Sep 15;201-202:163-5 [18639938.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurol. 2010 Apr;257(4):509-17 [20035430.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4712-25 [18448648.001]
  • (PMID = 20199689.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Vimentin; 0 / ZIC1 protein, human; 0 / ZIC2 protein, human; 0 / ZIC5 protein, human
  • [Other-IDs] NLM/ PMC2838823
  •  go-up   go-down


82. Chang CW, Wang LC, Lee JS, Tai SH, Huang CY, Chen HH: Orbitozygomatic approach for excisions of orbital tumors with 1 piece of craniotomy bone flap: 2 case reports. Surg Neurol; 2007;68 Suppl 1:S56-9; discussion S59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbitozygomatic approach for excisions of orbital tumors with 1 piece of craniotomy bone flap: 2 case reports.
  • BACKGROUND: Orbital tumors are classified as primary and secondary.
  • For primary entities, there are variable pathologies with benign and malignant natures.
  • Many of the orbital tumors should be excised through neurosurgical approaches.
  • We reported 2 cases of orbital tumors, which were clearly disclosed by magnetic resonance imaging.
  • This approach assures maximum exposure for successful en bloc excisions of these tumors with minimal bone loss, so the cosmetic results are satisfactory.
  • CONCLUSIONS: Even though most orbital tumors are diagnosed by ophthalmologists, most of them should be operated on by neurosurgeons because neurosurgical approaches offer wide and safe surgical windows.
  • [MeSH-major] Craniotomy / methods. Neurosurgical Procedures / methods. Orbit / surgery. Orbital Neoplasms / surgery. Surgical Flaps / standards. Zygoma / surgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Aged. Female. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Lacrimal Apparatus / pathology. Lacrimal Apparatus / surgery. Lacrimal Apparatus Diseases / pathology. Lacrimal Apparatus Diseases / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Middle Aged. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Neurol. 2008 Dec;70 Suppl 1:S1:91-2 [18614213.001]
  • [CommentIn] Surg Neurol. 2009 Dec;72 Suppl 2:S86 [19944830.001]
  • (PMID = 17963927.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Castelli J, Thariat J, Benezery K, Courdi A, Chanalet S, Paquis P, Doyen J, Frenay M, Mammar H, Bondiau PY: [Spinals and paraspinals tumors treated by CyberKnife: feasibility and efficacy]. Cancer Radiother; 2010 Jan;14(1):5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spinals and paraspinals tumors treated by CyberKnife: feasibility and efficacy].
  • [Transliterated title] Tumeurs spinales et paraspinales traitées par irradiation stéréotaxique par CyberKnife((R)) au centre Antoine-Lacassagne de Nice.
  • PURPOSE: Stereotactic radiotherapy using the CyberKnife has become a key treatment in the multidisciplinary management of secondary tumours, as well as primary benign or malignant tumours located within or adjacent to vertebral bodies and the spinal cord.
  • The main advantages are better sparing of the spinal cord and the possibility of increasing the dose to the tumour target volume.
  • [MeSH-major] Radiosurgery. Spinal Neoplasms / mortality. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chordoma / mortality. Chordoma / surgery. Disease-Free Survival. Feasibility Studies. Female. Hemangioma / mortality. Hemangioma / surgery. Humans. Male. Meningeal Neoplasms / mortality. Meningeal Neoplasms / surgery. Meningioma / mortality. Meningioma / surgery. Middle Aged. Neoplasm Metastasis. Neurilemmoma / mortality. Neurilemmoma / surgery. Osteosarcoma / mortality. Osteosarcoma / surgery. Radiation Dosage. Radiometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20005764.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


84. Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fèvre-Montange M: Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol; 2008 Sep-Oct;27(5):334-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, which originate from arachnoid cells, represent one of the largest subgroups of intracranial tumors.
  • They are generally benign, but can progress to malignancy.
  • C-Myc mRNA and protein levels were not grade-related, but validated subdivision of the 36 benign meningiomas into two groups, Groups IA and IB, based on histological and clinical features (Ki-67-proliferative index, absence or presence of mitoses, rate of recurrence and incidence of perilesional edema).
  • In addition to histopathological grading, c-Myc expression may be useful in predicting tumor recurrence in patients with low-grade meningiomas.
  • Furthermore, the high expression of sst2 in meningothelial meningioma suggests the possibility of a different tumorigenesis process in this meningioma subtype and may open perspectives for the diagnosis and therapy of this subtype using somatostatin as an antiproliferative agent.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neurofibromin 2 / biosynthesis. Proto-Oncogene Proteins c-myc / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptors, Somatostatin / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808065.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Neurofibromin 2; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


85. Yoo-Jin K, Kim Y, Bochem N, Ketter R, Henn W, Feiden W: [Meningiomas: multiparametric approach for risk stratification and grading]. Pathologe; 2008 Nov;29(6):428-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of the generally benign meningiomas is mainly an issue of the likelihood of recurrence, which increases with WHO grade (7-20% in WHO grade I, 29-40% in WHO grade II, and 50-78% in WHO grade III meningiomas).
  • Among clinical parameters the most important prognostic factor is the completeness of neurosurgical tumor resection.
  • As the cutoffs of the mitotic index (MI) are defined for each grade by the WHO classification of brain tumors and because the MI can be applied as the sole grading criterion, the reliable and reproducible assessment of the MI is crucial for an appropriate risk stratification.
  • [MeSH-major] Chromosomes, Human, Pair 1. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Am J Clin Pathol. 2007 Jul;128(1):118-25 [17580279.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):252-8 [16040297.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Nature. 1967 Oct 7;216(5110):84-5 [6050684.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):879-86 [9258258.001]
  • [Cites] Clin Neuropathol. 2006 Mar-Apr;25(2):67-73 [16550739.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):61-9; discussion 69-70 [18300892.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1473-80 [17557299.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 18810442.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Ferrer M, Schulze A, Gonzalez S, Ferreiro V, Ciavarelli P, Otero J, Giliberto F, Basso A, Szijan I: Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases. Neurosci Lett; 2010 Aug 9;480(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of them are benign however, their location in the nervous system has harmful effects on important cranial and spinal structures.
  • These tumors are developed as the outcome of NF2 gene (22q12) inactivation.
  • The NF2 protein, merlin or schwannomin belongs to the Ezrin, Radixin, Moesin (ERM) family involved in the cytoskeletal network and has a tumor suppressor function.
  • Inactivating mutations occur as "de novo" (more frequently) or as inherited, and most of them are frameshift or nonsense.
  • [MeSH-minor] Adolescent. Adult. Aged. Argentina. Child. Ependymoma / genetics. Ependymoma / physiopathology. Female. Haplotypes. Humans. Male. Meningeal Neoplasms / genetics. Meningeal Neoplasms / physiopathology. Meningioma / genetics. Meningioma / physiopathology. Middle Aged. Molecular Diagnostic Techniques. Mutation. Pedigree. Young Adult


87. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102 Suppl:134-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • The tumor location was the sphenoid ridge in one case, petroclival in two, tentorium in one, and parasagittal region in one.
  • The mean tumor volume was 10.5 cm3, the mean margin dose was 13.4 Gy (median 14 Gy), and the mean maximum dose was 27.5 Gy (median 24.1 Gy).
  • At the time of GKS three tumors were associated with cyst, of which two enlarged after radiosurgery.
  • Three cysts developed de novo after GKS.
  • Histological examination demonstrated various findings such as tumor necrosis, proliferation of small vessels, vascular obliteration, and hemosiderin deposits.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / surgery. Cysts / etiology. Cysts / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications. Radiosurgery / instrumentation

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662796.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Mineo JF, P-Ruchoux MM, Pasquier D, Rigolle H, Assaker R: [Primitive malignant melanoma arising in a spinal nerve root. A case report]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The T1-weighted MRI images showed a tumor hyperintensity, the T2-weighted images showed tumor isointensity and mild contrast enhancement.
  • Due to the scalloping of L3/L4 foramen with root enlargement and slow evolution (more than one year between the first symptom and surgery without clinical worsening), the initial preoperative diagnosis was L3 schwannoma.
  • The tumor was composed of irregular melanocytoid cells with high proliferation index (20%).
  • So, the final diagnosis was intradural primitive malignant melanoma.
  • Radiotherapy was performed on the site of the tumor.
  • The most common tumor with root enlargement and bony scalloping is the benign schwannoma.
  • Despite the above described radiological features, MRI characteristics (hyperintensity when images are T1-weighted) suggest a melanocytic tumor, a tumor with a high adipose component or an intratumoral bleeding.
  • Specific MRI sequences can eliminate adipose tissue tumor, but diagnosis between melanin and methemoglobin is still difficult.
  • According to the index of proliferation, a primitive central melanocytic lesion can be a meningeal melanocytoma (considered as benign) or a primitive malignant melanoma.
  • These tumors show identical protein expressions in immunohistochemistry, and their prognosis is very variable (some long-term remissions are reported for malignant melanomas and fast disseminations are described for meningeal melanocytomas treated by sub-total surgery).
  • The histological features of malignant lesion with benign clinical features lead to interrogation upon the actual pathologic classification.
  • [MeSH-major] Melanoma / pathology. Spinal Neoplasms / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Cell Proliferation. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Melanins / metabolism. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Neurologic Examination. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840974.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


89. Chang SW, Gore PA, Nakaji P, Rekate HL: Juvenile intradural chordoma: case report. Neurosurgery; 2008 Feb;62(2):E525-6; discussion E527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We report the youngest known case of a prepontine intradural chordoma.
  • These tumors are exceedingly rare.
  • Close follow-up is warranted because we postulate that this tumor exists in a biological continuum between benign notochordal hamartomatous remnants and typical invasive chordomas.
  • [MeSH-major] Chordoma / pathology. Chordoma / surgery. Dura Mater / pathology. Dura Mater / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382292.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Nakaya K, Chernov M, Kasuya H, Izawa M, Hayashi M, Kato K, Kubo O, Muragaki Y, Iseki H, Hori T, Okada Y, Takakura K: Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index. Minim Invasive Neurosurg; 2009 Oct;52(5-6):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Thirty-four intracranial meningiomas with known detailed histopathological diagnosis were analyzed.
  • Tumors of WHO histopathological grades I, II, and III were diagnosed in 24, 3, and 7 cases, respectively.
  • In 26 cases the treatment was done at the time of tumor recurrence.
  • Median volume of the neoplasm at the time of GKR was 4.1 mL (range: 0.4-43.1 mL).
  • Histopathological grade II or III (p<0.0001), MIB-1 index 3% and more (p=0.0004), and non-skull base location (p=0.0026) of the tumor showed negative associations with progression-free survival in multivariate analyses.
  • Actuarial progression-free survival at 5 years after GKR for benign and non-benign meningiomas constituted 100 and 45%, respectively (p<0.0001).
  • CONCLUSION: Radiosurgery is a highly effective management option for benign intracranial meningiomas, but growth control of non-benign ones is significantly worse.
  • [MeSH-major] Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Radiosurgery
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Proliferation. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077361.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / MIB-1 antibody
  •  go-up   go-down


91. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


92. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e4 [15669815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


93. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas.
  • Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II).
  • We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN.
  • In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2004 Feb;61(2):149-55; discussion 155-6 [14751627.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Neuro Oncol. 2010 Jan;12(1):58-70 [20150368.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):375-83 [10470810.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29 [12013531.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):465-75 [10861844.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):212-26 [18292776.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):199-207 [19801161.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):819-30 [17168734.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):203-7 [19048398.001]
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


94. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg; 2007 Jun;106(6):1034-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because multiple growth factor receptors have been identified in these tumors, the authors sought to assess the capacity of the expression patterns of a subset of these receptors to stratify meningioma cases.
  • METHODS: Eighty-four meningiomas were analyzed, including 36 benign, 29 atypical, and 19 malignant lesions.
  • Survival analyses were performed using follow-up data obtained in patients with newly diagnosed tumors.
  • Immunoreactivity for EGFR was observed in 47% of benign, 48% of atypical, and 42% of malignant tumors.
  • Staining for BFGFR was identified in 89% of benign, 97% of atypical, and 95% of malignant lesions.
  • Mean MIB-I indices for benign, atypical, and malignant cases were 3.6 (range 0.5-15.3), 8.2 (range 1.5-23.1) and 18.3 (range 1.0-55.8), respectively.
  • This association was not evident in cases of benign or malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564176.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Fibroblast Growth Factor; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


95. Yilmaz Z, Sahin FI, Atalay B, Ozen O, Caner H, Bavbek M, Demirhan B, Altinörs N: Chromosome 1p36 and 22qter deletions in paraffin block sections of intracranial meningiomas. Pathol Oncol Res; 2005;11(4):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequent benign tumors of the intracranial cavity.
  • The clinical material consisted of paraffin-embedded tissue sections from 50 patients who were surgically treated and had histopathologic diagnosis of an intracranial meningioma.
  • On the other hand, no alterations were documented in the frequency of these chromosomal alterations according to the grade of meningiomas, suggesting that malignant progression of these tumors depends on other, more relevant, genetic changes.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 22 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2567-73 [8640707.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):38-48 [12885461.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):219-23 [9822846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9275-9 [2892198.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):95-100 [9614906.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 1;144(1):65-8 [12810258.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):119-24 [11369054.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):479-85 [9386781.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):160-4 [12127400.001]
  • (PMID = 16388319.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


96. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, Takano S, Matsumura A: New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol; 2008 Dec;18(12):2901-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases of 31 meningioma patients (27 benign and 4 nonbenign meningiomas) that underwent single-voxel 1H-MRS (PRESS sequence, TR/TE = 2,000 ms/68, 136, 272 ms) were retrospectively analyzed.
  • N-acetyl compounds(NACs) were observed in nine cases whose voxels were completely limited within the tumors, indicating that meningiomas might have endogenous NACs.
  • Lip not only represented micronecrosis in nonbenign meningiomas, but also reflected microcystic changes or fatty degeneration in benign meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choline / analysis. Creatine / analysis. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 2001 Aug;14(5):307-17 [11477651.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):85-9 [1650244.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):55-60 [11147898.001]
  • [Cites] Radiology. 1989 Aug;172(2):541-8 [2748837.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neuroradiology. 2007 Feb;49(2):121-7 [17086406.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] Magn Reson Imaging. 1995;13(7):1019-29 [8583866.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3983-93 [11051247.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):769-75 [11395554.001]
  • [Cites] J Neurol. 1996 Oct;243(10):706-14 [8923303.001]
  • [Cites] Radiology. 1992 Jun;183(3):701-9 [1584924.001]
  • [Cites] Magn Reson Imaging. 1995;13(6):853-69 [8544657.001]
  • [Cites] Neuroradiology. 2003 Mar;45(3):129-36 [12684713.001]
  • [Cites] Neuroradiology. 2002 Jul;44(7):574-8 [12136358.001]
  • [Cites] J Comput Assist Tomogr. 1994 Sep-Oct;18(5):705-13 [8089316.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Magn Reson Imaging. 1993;11(1):107-18 [8423713.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] NMR Biomed. 1992 Jan-Feb;5(1):43-7 [1550709.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4 [7808603.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):1-15 [8770242.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):99-108 [10982150.001]
  • [Cites] Clin Neuropathol. 1988 Jan-Feb;7(1):16-21 [3370860.001]
  • (PMID = 18641997.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


97. Asthagiri AR, Helm GA, Sheehan JP: Current concepts in management of meningiomas and schwannomas. Neurol Clin; 2007 Nov;25(4):1209-30, xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas and schwannomas are the two most common extra-axial intracranial tumors in adults.
  • Since their initial discovery, these often-benign lesions have shared a parallel metamorphosis in their management.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy. Neurilemmoma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964032.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


98. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Neurosurg Rev. 2008 Oct;31(4):421-30; discussion 430 [18521636.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1147-55 [8083085.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16 [19319527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1315-24 [10613328.001]
  • [Cites] Methods Enzymol. 2007;435:297-321 [17998060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Radiologe. 1998 Mar;38(3):228-34 [9577869.001]
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Rahman M, Murad GJ, Bova F, Friedman WA, Mocco J: Stereotactic radiosurgery and the linear accelerator: accelerating electrons in neurosurgery. Neurosurg Focus; 2009 Sep;27(3):E13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiosurgery is truly minimally invasive, delivering therapeutic energy to an accurately defined target without an incision, and has been used to treat a wide variety of pathological conditions, including benign and malignant brain tumors, vascular lesions such as arteriovenous malformations, and pain syndromes such as trigeminal neuralgia.
  • [MeSH-minor] Brain Neoplasms / surgery. History, 20th Century. Humans. Meningeal Neoplasms / surgery. Minimally Invasive Surgical Procedures / methods. Monitoring, Intraoperative. Neurosurgical Procedures / history. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Radiotherapy / methods. Treatment Outcome. Trigeminal Neuralgia / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722815.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


100. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening brain magnetic resonance (MR) imaging with gadolinium had detected multiple homogeneously enhanced tumors in the right convexity and in the anterior and posterior thirds of the falx cerebri after surgery for osteosarcoma in his right leg at age 52 years.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Review of the literature found meningiomas associated with Werner syndrome occur about two times more frequently in men than in women, and typically in the fourth decade.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • Patients with meningioma associated with Werner syndrome should be carefully followed up to detect the occurrence of other extracranial tumors such as sarcoma by brain MR imaging, echography, or body computed tomography.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications






Advertisement